Lasa Supergenerics Ltd. engages in the manufacture of veterinary preparations. The company is headquartered in Mumbai, Maharashtra and currently employs 89 full-time employees. The company went IPO on 2017-09-21. The firm is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs and others. The company specializes in catalyst chemistry and manufactures anthelmintic/veterinary API products. The firm's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol and others. Its animal feed ingredients include potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide and vanadyl sulfate. Its reagents for therapeutic use include cetylpyridinium chloride, bismuth subsalicylate and sodium selenite. The firm's manufacturing facility is located at Mahad and Chiplun, Maharashtra.

Frequently Asked Questions